Infection Control & Wound Care

Advanced Medical Materials —
From Research to Production

ETC Innovation develops next-generation wound dressing materials, antimicrobial substrates, and infection control products — integrating materials science, manufacturing capability, and regulatory readiness under one roof.

Our Portfolio Companies Manufacturing Capabilities
3
Equity positions in medical IP
Pilot → Production
Full manufacturing scale
FDA Pathway
Regulatory compliance dev.
USA
Domestic materials & mfg.
About ETC Innovation

A vertically integrated MedTech development company

ETC Innovation specializes in process and product development of medical materials for bandages and infection control. We hold equity positions in three companies with unique patented devices and IP — DrySee, FiteBac WoundCare, and SubPac Wound Care — and invest in the materials science, manufacturing equipment, and regulatory compliance infrastructure to bring those products to market.

Products & Pipeline

From concept to clinical application

Our pipeline spans active wound dressings, wetness indication materials, infection control substrates, and novel antimicrobial delivery systems — each at a defined development and regulatory stage.

Subdermal Wound Dressings

SubPac® — FDA 510(k)-cleared patented subdermal incisional dressing with PHMB wicking strips and silver alginate. Zero infections across all reported cases.

FDA 510(k) Cleared

Wetness Indication Materials

DrySee® HydroChromatic indicator system — exclusive manufacturing license. Color-change technology for wound dressings, foam dressings, and IV site dressings.

In Production

K21 Antimicrobial Integration

FiteBac K21 QAS molecule — FDA NME recognition, active NDA 128706, composition of matter patents in US, Europe & China. ETC introducing to infection control market.

Market Introduction
Manufacturing

Pilot to production — under one roof

Our USA-based manufacturing site houses pilot-scale and production-ready equipment, giving partners a direct path from formulation to compliant commercial output — with no change of custody.

Pilot-Scale Equipment
Process development and prototype runs in a traceable, documented environment built for complex medical dressing manufacture.
Production Equipment
Commercial-scale lines for wound dressings and infection control substrates, including highly complex automated assembly.
Materials Development
In-house formulation for polyurethane, silicone, alginate, and antimicrobial matrix systems — from raw material to finished dressing.
Regulatory Testing
Structured compliance protocols aligned with FDA 510(k) and ISO 13485 requirements, supporting full regulatory submission packages.
Portfolio Companies

Three equity positions in proven medical IP

ETC Innovation holds equity in and produces materials for three companies with deeply validated technology, patented devices, and active regulatory dossiers. Click any company to learn more.

SubPac Wound Care

Subdermal Wound Dressing

FDA 510(k)-cleared patented subdermal incisional dressing. Integrates PHMB wicking strips and silver alginate. Zero infections across all reported clinical cases including patients in septic shock and contaminated wound classifications.

Equity Holder · Manufacturer

View SubPac® Page →
DrySee®

Wetness Indication Technology

Patented HydroChromatic indicator materials that change color upon moisture contact. ETC Innovation holds the exclusive manufacturing license — producing the indicator materials used in DrySee wound dressings and foam dressings.

Exclusive Manufacturing License

Visit DrySee.com →
FiteBac™

K21 Antimicrobial Molecule

K21 quaternary ammonium silane — FDA NME recognition, active NDA 128706, composition of matter patents in US, Europe, and China. Bactericidal, viricidal, fungicidal with biofilm inhibition.

Market Introduction Partner

Visit FiteBacWoundCare.com →
Riverworks

Where blue-sky research becomes real-world innovation

Riverworks is our affiliated applied research entity — dedicated to long-horizon exploration of advanced materials, novel IP combinations, and emerging clinical applications. Ideas that originate at Riverworks feed directly into ETC Innovation's development pipeline.

Learn about Riverworks →
News & Updates

Latest from ETC Innovation

March 2026

SubPac® advances toward expanded clinical evaluation across surgical disciplines

Following zero-infection outcomes in initial case series, SubPac® Wound Care is being evaluated for broader application across colorectal, trauma, and high-risk surgical populations.

January 2026

ETC Innovation introduces FiteBac K21 molecule to the infection control and wound care market

K21 QAS — FDA NME recognized, active NDA on file — entering advanced wound care as a next-generation antimicrobial substrate component.